Abstract: The problem to be addressed by the present invention is to provide improved recombinant Fc?RIIb and Fc?RIIa that do not require refolding and exhibit high productivity and thermal stability, and to provide a method for producing the same. Said problem is solved by improved recombinant Fc?RIIb comprising at least the amino acid residues of the extracellular domain of human Fc?RIIb (No. 43 to No. 215 in UniProt No. P31994), wherein, in said amino acid residues, at least one amino acid substitution has occurred at a position corresponding to No. 82, 94, 98, 104, 105, or 139 in UniProt No. P31994. Said problem is also solved by improved recombinant Fc?RIIa comprising at least the amino acid residues of the extracellular domain of human Fc?RIIa (No. 34 to No. 206 in UniProt No. P12318-1), wherein, in said amino acid residues, at least one amino acid substitution has occurred at a position corresponding to No. 73, 85, 89, 95, 96, or 130 in UniProt No. P12318-1.

Abstract: The present invention relates to Cutibacterium granulosum GENSC02 strain (KCTC 13597BP). The present invention also relates to a composition comprising the strain or its culture, and use thereof. The present invention is effective in improvement, prevention or treatment of acne, atopic dermatitis or skin inflammation by fine dust.

Abstract: Provided herein are pharmaceutical compositions comprising a bacterial consortium and one or more pharmaceutically acceptable excipients. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or treatment of dysbiosis, dysbiosis associated conditions, inflammation, and autoimmune diseases.

Abstract: The present disclosure provides novel adjuvants which may be used in combination with one or more antigens to augment, modulate or enhance a host immune response to the one or more antigens. The adjuvants are based on sialic acid binding molecules and may be combined with any type of antigen. The adjuvants may be formulated for mucosal and/or intranasal administration.

Abstract: The present invention relates to the field of immunology and to methods for inducing an M1/Th1 dominated immune response in an M2 macrophage dominated and/or Th2/Treg dominated human patient or animal. These methods are useful for developing therapies for treating or preventing M2 macrophage mediated and/or Th2/Treg mediated disease states.

Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Abstract: The present invention provides, among other things, cartridges for multiplexed antimicrobial susceptibility testing (AST), single cartridges useful for both AST and quality control of AST, and systems and methods relating thereto.

Abstract: Provided is a pharmaceutical composition for the prevention, alleviation, or treatment of inflammatory diseases, metabolic diseases, and cancer, comprising a Streptococcus pyogenes culture broth or a protein isolated from the culture broth as an active ingredient. The inventors of the presently claimed subject matter confirmed that, when administered to inflammatory disease, metabolic disease, and cancer models, a Streptococcus pyogenes culture broth or a protein isolated from the culture broth exhibited anti-inflammatory, anti-obesity, liver function-improving, and anticancer effects, and thus the Streptococcus pyogenes culture broth or the protein isolated from the culture broth according to the presently claimed subject matter can be effectively used to develop a drug, a health functional food, an inhalant, a cosmetic composition, or the like for preventing inflammatory diseases, metabolic diseases, and cancer, or alleviating or treating symptoms thereof.

Abstract: The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof (FIG. 6B).

Abstract: The invention provides a probiotic formulation that includes an LDH-deficient mutans streptococcus strain and an attenuated S. oralis strain. S. uberis strains can be included in the probiotic formulation. Such a probiotic formulation is suitable for transiently colonizing the oral cavity with beneficial bacteria.

Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.

Abstract: Assays, arrays, and methods for distinguishing a bacterial infection from a viral infection are disclosed. The antibiotic crisis is in part driven by over prescription of antibiotics. There is a tendency, particular in pediatrics, to give an antibiotic even for viral infections. Thus, embodiments herein are directed to the problem of distinguishing a bacterial infection from a viral infection to reduce unnecessary antibiotic usage.

Abstract: A main controller of an immunological test apparatus counts an elapsed time TP. An information output unit outputs required determination time information regarding a required determination time so as to be associated with information of a determination result. The required determination time information is at least information indicating that the elapsed time TP exceeds a set time TS at which sensitization processing, in which a chemical solution for sensitizing the coloration state of a reagent that is combined with influenza virus to be colored is spread onto a carrier, is started, that is, information indicating that the sensitization processing has been performed.

Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.

Abstract: The present invention generally relates to therapeutic compositions and methods for treating cancer patients. The compositions and methods can increase efficacy of an anti-cancer therapy, or treat, prevent, or inhibit an oncology-treatment induced condition (OTIC) induced by an anti-cancer therapy. The therapeutic compositions comprise microbial compositions and, optionally, an anti-cancer therapeutic agent. The methods comprise administering a therapeutic composition comprising a microbial composition and administering an anti-cancer therapy.

Abstract: A composition and method for preventing and/or treating an E. coli-based infection in an animal is described.

Abstract: The present invention relates to tick polypeptides and compositions comprising the same, which are useful for treatment or prophylaxis of tick infestation in a subject.

Abstract: The invention relates to the field of medicine, specifically to the field of treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting a bacterial Staphylococcus cell. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with Staphylococcus infection.

Abstract: The present invention relates to an analytical in vitro process for predicting the therapeutic effectiveness of at least one pharmaceutical compound in the treatment of leukemia and/or lymphoma, the process analysing the transmembrane potential of mitochondria in cells isolated from a patient by quantification of fluorescence emitted from a dye indicating induction of apoptosis.

Abstract: The present invention provides new pharmaceutical and vaccine compositions comprising Treponema spp. bacterins, supplemented with antigens from Treponema spp. or other digital dermatitis causative pathological agents such as but not limited to D. nodosus or F. necrophorum, for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. The present invention also identifies Treponema pedis and Treponema phagedenis as two of the etiologic agents of digital dermatitis (DD) in mammals, in particular ungulate digital dermatitis. The invention therefore also provides isolated cultures of Treponema pedis and Treponema phagedenis for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. In addition, the present invention provides methods of diagnosing DD by detecting infection with a series of specific Treponema antigens.